The investıgatıon of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patıents
| Autor: | Müjgan Cengiz, Ahmet Ozaydin, Galip Dedekarginoglu, Anil Cagla Ozkilic |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Nephrology medicine.medical_specialty Genotype Urology Polymerase Chain Reaction Gastroenterology Statistics Nonparametric law.invention chemistry.chemical_compound GSTP1 law Internal medicine medicine Humans neoplasms Gene Polymerase chain reaction Glutathione Transferase chemistry.chemical_classification Genetics Polymorphism Genetic Bladder cancer integumentary system Superoxide Dismutase business.industry Glutathione Middle Aged medicine.disease Enzyme Urinary Bladder Neoplasms chemistry Case-Control Studies Female business |
| Zdroj: | International Urology and Nephrology. 39:1043-1048 |
| ISSN: | 1573-2584 0301-1623 |
| DOI: | 10.1007/s11255-007-9179-9 |
| Popis: | Glutathione S transferases (GSTT1, GSTM1, GSTP1) are enzymes that activate the detoxification of endogenous and exogenous agents. The genetic polymorphism in these genes may change the response of individuals to environmental toxicants. The genetic polymorphisms of GSTT1, GSTM1, GSTP1 have been studied extensively in the determination of individual cancer risks. Some studies showed a strong relationship between polymorphism of GSTs and superoxidedismutase enzymes. Using the polymerase chain reaction (PCR) the prevalence of genetic polymorphisms of GSTT1, GSTM1 and MnSOD (Manganese Superoxide Dismurase) was investigated in 104 cases and controls to seek any association with the risk of bladder cancer. The frequency of GSTT1 +/+ polymorphism was 65% (33/51) in the cases and 79% (42/53) in the controls. The frequency of the GSTM1 +/+ polymorphism was 33% (17/51) in the cases and 58% (31/53) in the controls. The frequency of the GSTM1 null genotype was 42% (22/53) in the controls and 68% (34/51) in the patients. The frequency of the SOD AA genotype was 36% (17/51) in the cases and 33% (19/53) in the controls. There was no association between the GSTT1 and SOD polymorphism and bladder cancer incidence. The incidence of the GSTM1 null genotype was increased in bladder cancer patients compared to controls (OR = 1.755, 95% CI = 1.119-2.751). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink